Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, ...

Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with ...

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

For years, chimeric antigen receptor (CAR) T cell therapies have led the way in cell-based immunotherapy, offering hope to many patients with certain blood cancers. But now, researchers believe the ...

Research led by Friedrich-Alexander-Universität Erlangen–Nürnberg provides evidence that teclistamab may offer therapeutic ...

A protein notorious for its role in Alzheimer’s disease may hold the key to supercharging the aging immune system, according to new research. Scientists have found that a byproduct of amyloid-beta ...

CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory ...